

2019-452

**Vanessa Cullins Hopkins MD, MPH, MBA, Vice President and Operations Manager
For
Pebo Enterprises Corporation, Pebo Enterprises Georgia LLC, PeboVan Tax
Liens and Deeds LLC, and VanPebo Florida LLC**

Vanessa Elaine Cullins, MD, MPH, MBA, FACOG

Home Address:

3283 Edgewood Avenue, West
Jacksonville, FL 32209
Phone: (904)764-8816
Email: vecullins@gmail.com

Business Address:

3283 Edgewood Avenue West
Jacksonville, Florida 32209
Phone: (904)8594959
Email: vecullins@aol.com

BORN

May 24, 1957 – Covington, KY

DEGREES

H.S.	Jean Ribault High School, Jacksonville. Florida	1975
B.S.	Spelman College, Atlanta, Georgia	1979
M.D.	The Johns Hopkins University, School of Medicine	1983
M.P.H.	The Johns Hopkins University, School of Hygiene & Public Health	1984
M.B.A.	University of Pennsylvania, The Wharton School	1998

QUALIFYING EXAMS/CERTIFICATION

Flex	1983
American Board of Obstetrics and Gynecology – Board Certified	1991

MAINTENANCE OF CERTIFICATION

Annual Board Certification (ABOG ABC)	2001-2014
---------------------------------------	-----------

MEDICAL LICENSE

Maryland – D0036020

INTERNSHIP AND RESIDENCY

The Johns Hopkins University School of Medicine/Johns Hopkins Hospital Department of Gynecology and Obstetrics	1984-1988
---	-----------

FELLOWSHIP

Fellow, Primary Care Obstetrics and Gynecology The Johns Hopkins University School of Medicine	1988-1990
---	-----------

Department of Gynecology and Obstetrics

Preceptor: George R. Huggins, M.D.
Chairman, Department of OB/GYN (1987-2001)
Johns Hopkins Bayview Medical Center
Baltimore, MD

ACADEMIC APPOINTMENTS

Assistant Professor of Gynecology and Obstetrics **1990-1998**
Johns Hopkins University School of Medicine
Baltimore, MD

WORK EXPERIENCES

Vice President and Operations Manager **2016-Present**
For Pebo Enterprises Corporation, Pebo Enterprises Georgia LLC,
PeboVan Tax Liens and Deeds, and VanPebo Florida LLC
3283 Edgewood Avenue West
Jacksonville, Florida 32209
(904) 859-4959

As Vice President and Operations Manager of the S Corporations and LLC's listed above, I researched and implemented an organizational Structure that will allow my husband (President of all listed entities) and myself to become real estate entrepreneurs who invest in single and multi-family, high quality, and aesthetically pleasing, low income housing. Through these business entities we raise capital for acquisition and renovation of real estate. The companies buy distressed assets and with other people's money secured as a mortgage. The entities above work with a power team consisting of a realtor, lenders, general contractor, title companies, insurance companies and CPA.

Vice President – External Medical Affairs **2011-2016**
Planned Parenthood Federation of America (PPFA)
434 West 33rd Street
New York, NY 10001
(212)261-4701

As Vice President of External Medical Affairs, I operate at the intersections of Public Policy, Communications, and Medical Services to provide leadership, voice, and assistance to junior and senior staff as they develop and execute strategies to: increase access to health care services, especially in areas of the country with highest unmet need; develop, maintain, and strengthen national and local partnerships with organizations and individuals with missions and goals that complement PPFA's missions, goals, and health services work; communicate truths and correct misperceptions about Planned Parenthood and reproductive health, especially preventive reproductive health; assist in execution of strategies that demonstrate the competitive high quality medical

services provided by Planned Parenthood affiliates; assist in developing research strategy along with communication of the impact of research conducted by Planned Parenthood affiliates. Day to day tasks include: media interviews focused on health care access, health disparities, reproductive health and well being, and medical services; panel presentations; facilitation of inter-divisional and inter-organizational work; providing support and assistance in tailoring and conveying preventive reproductive health messages to diverse audiences and stakeholders; and assisting in determining specific concrete, guidance about how to improve access to medical services.

Vice President – Medical Affairs

Planned Parenthood Federation of America (PPFA)
434 West 33rd Street
New York, NY 10001
(212)261-4701

2001-2011

Responsibilities included leadership and administrative management of the Medical Affairs Group of PPFA. This leadership involved complex coordination of multi-disciplinary teams across the nation, including non-PPFA entities. When I served as VP of Medical Affairs, Planned Parenthood consisted of the national offices and 99 affiliates that operated over 880 reproductive health centers in the United States. Then and now Planned Parenthood affiliate health centers provide family planning; primary care, including HIV immunizations; STI screening, diagnosis, treatment, and management; pre-natal care; abortion services; cervical cancer screenings with dysplasia diagnosis and management; breast cancer screening and care; peri-menopausal services; and select services for men. The Clinical Services Department of Medical Affairs was responsible for development of the Medical Standards and Guidelines for these services. Separately and in partnership with others across the Federation, Clinical Services used joint problem solving to develop projects and products that improved, enhanced and supported quality, standardization, and optimization of affiliate health care delivery. The Medical Affairs Division also consists of a Department of Research and a Department of Continuing Education and Special Projects. The Research Department served as a resource and provided opportunities for affiliates to partner with the national office to conduct research. Within this capacity, the Department of Research effectively served as a site management organization that worked with contract research organizations to assure protocol and regulatory compliance in addition to proper fiscal management. This department also assisted with writing and review of abstracts, presentations, and articles that emerged from research done in the federation. The Continuing Education and Special Projects Department designed, executed, and evaluated educational programs and materials that enhanced the performance of staff and enhance the quality of clinical services received by Planned Parenthood clients. To develop these evidence based programs, Continuing Education staff work collaboratively with external experts and cross-functional, multidisciplinary teams, whose members are representative of national office and affiliates' staff. Additionally, Medical Affairs provided technical assistance and support to other divisions of PPFA and affiliates. This technical assistance included consultation, reviews for medical accuracy, public relations and advocacy.
Budget: Approximately \$3 million/year.

- Member of Senior Management Team that is responsible for strategic direction and management of the national offices (\$70 million/year). The Senior Management Team also works closely with affiliate members of the Federation on Federation-wide issues and initiatives. (Budget of entire Federation is approximately \$500 million/year)
- Media work (print, television, radio) and external speaking engagements for affiliates and for the national office

In 2011, the Medical Affairs Division was consolidated into a new division, Health Services Support (HSS), which is charged with developing new business models for affiliates, optimizing existing business models, and facilitating affordable care act implementation. Departments formerly names clinical services, research, and medical continuing education continue to operate with expanded staff and responsibilities, in addition to responsibilities conveyed above.

Vice President/Medical Director – Technical Services **1998-2001**
 EngenderHealth (Formerly AVSC International)
 440 Ninth Avenue
 New York, NY 10001
 (212)561-8383

Responsibilities included:

- Member of the Executive Team which was responsible for strategic direction and management of this \$30-34 million agency
- Oversight and direction of Technical Teams responsible for providing technical support for reproductive health service delivery in over 40 countries worldwide
 - Teams managed included Clinical Services Support, Technical Resources Support, and Training teams.

Attending Physician, Staff – Department of Gynecology & Obstetrics **1988-1998**
 Johns Hopkins Bayview Medical Center
 4940 Eastern Avenue
 Baltimore, MD 21224
 (410)550-0335

Assistant Professor – Department of Gynecology & Obstetrics **1990-1998**
 The Johns Hopkins University, School of Medicine
 Baltimore, MD 21224

Acting Director **1990-1998**
 Bureau of Primary Care and Reproductive Health
 (Re-named Bureau of Adolescent Reproductive and Women’s Health)
 Baltimore City Health Department
 Baltimore, MD

- Organized and directed a management team that assessed, revised, and implemented several clinical processes and procedures, including patient flow, billing, follow-up, laboratory and screening tests, and medication inventory control.

- Oversight and allocation of resources based on bureau goals and a 2.1 million dollar budget
- Acquired additional funding (\$300,000) to enhance operation of the Healthy Teens and Young Adults program
- With the management team, actively restructured Bureau organizational structure to potentiate problem solving through cross functional teams
- Developed clinical protocols for reproductive health care
- Supervised staff of more than forty

Director Reproductive Health Policy
 Bureau of Primary Care and Reproductive Health
 Baltimore City Health Department

1994-1997

Responsibilities included development and oversight of Clinic Operations, Quality Assurance, Billing, Medical Records, Clinical Protocol Development and Medical Staff Supervision

AWARDS/HONORS

Laurel and Clarence Koennecke Award for Excellence in Gynecology
 Presented by The Johns Hopkins University
 Department of Gynecology and Obstetrics

1979

Distinguished Alumni Grand Rounds Lecturer for the Johns Hopkins Department of Gynecology and Obstetrics Kelly Society
 Presented Inaugural Lecture – Johns Hopkins Department of Gynecology and Obstetrics

2012

Distinguished Medical Alumna Award for the Class of 1983
 Johns Hopkins University School of Medicine

2013

PROFESSIONAL SOCIETY MEMBERSHIPS

American Congress of Obstetrics and Gynecology (Fellow)
 American Medical Association
 Association of Reproductive Health Professionals
 National Medical Association
 The Johns Hopkins Medical and Surgical Association

ADVISORY POSITIONS & COMMITTEE MEMBERSHIPS

2013-2014 Member, ACOG Well Woman Guidelines Task Force

2008-2011 Member, CDC Work Group
 U.S. Medical Eligibility Guidelines for Contraception

2007-2016 Member, Board of Directors
 The National Campaign to Prevent Teen and Unplanned Pregnancy

1994-2009 Member, Board of Directors
Association of Reproductive Health Professionals

2009-2014 Member, Board of Directors
Reproductive Health Technologies Project

2010-2013 Member, Institutional Review Board
Population Council

2008-2016 Member, Steering Committee
Oral Contraceptives Over-the-Counter (OCs OTC) Working Group

2006-2016 Member, OCs OTC Working Group

2001-2016 Founding Member, Advanced Practice Clinician (APC) Working Group

2001-2016 Member, Board of Trustees
International Contraceptive Access (ICA) Foundation

1995-2005 Member, Board of Directors
Norplant Foundation (renamed the Contraception Foundation, 2002)

2002-2004 Member, OB Subcommittee
New York State Department of Health
Committee for the Care of Women with HIV Infection

2000-2003 Subcommittee Chair International Subcommittee
American Medical Women's Association, Reproductive Health Initiative

2001-2002 Member, Editorial Advisory Board
The Contraception Report

1999-2001 Member, Board of Directors
National Family Planning and Reproductive Health Association

1995-1998 Treasurer, Association of Reproductive Health Professionals (ARHP)

1995-1998 Hospital Provider Representative, Region III
Chlamydia Project, Advisory Committee

1993-1997 Member, Governor's Council on Adolescent Pregnancy

1995-1997 Member, Editorial Board
Johns Hopkins Women's Health Newsletter

1994-1997 Member, National Medical Committee
Planned Parenthood Federation of America

- 1992-1997 Member, Board of Directors
Planned Parenthood of Maryland
- 1992-1997 Chair, Affiliate Medical Committee
Planned Parenthood of Maryland
- 1989-1997 Member, Affiliate Medical Committee
Planned Parenthood of Maryland
- 1995 Task Force Leader to Revise Region Study Protocols
III Chlamydia Project
- 1993-1995 Development and Implementation of Primary Care Gynecologic
Curriculum for General Internal Medicine Residents at the Johns Hopkins
Bayview Medical Center
- 1990-1995 Member, Medical Records Committee
Johns Hopkins Bayview Medical Center
- 1993-1994 Member, Credentials Committee
Johns Hopkins Bayview Medical Center
- 1992-1994 Member, Maryland Commission on Infant Mortality
- 1992-1994 Member, Family Planning Committee
Healthy Start Program
- 1992-1994 Member, Board of Directors
Health Mothers, Health Babies
- 1991-1994 Member, Quality Assurance Committee
Maryland Planned Parenthood
- 1990-1994 Editorial Board, "Woman to Woman" Newsletter
Maryland Planned Parenthood
- 1993 Consultant, Norplant Launch (Great Britain)
Roussel Pharmaceuticals
- 1989-1990 Member, Health Advisory Council
Department of Education, Baltimore City Schools

PHARMACEUTICAL ADVISORY BOARDS

- 2009-2010 Teva Women's Health "Contraception in America" Steering Committee
- 2007-2008 Wyeth Multicultural Advisory Board
- 2007-2008 Merck HPV Young Adult Primary Care Advisory Board

2007-2008 Ortho Women's Health and Urology OB/GYN Advisory Board

2006-2007 Merck HPV OB/GYN Advisory Board

COMPLETED RESEARCH FUNDING (Research list only includes projects up and until Dr. Ashlesha Patel was hired as Senior Medical Director for Research in 2009. Upon hiring Dr. Patel, I began providing gross oversight of the department of research and, therefore, I do not list the research completed or in progress since 2009.)

2006-2008 \$2 million – HRA Pharma: Protocol 2914-005, A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse – FDA Pivotal Trial involving 17 Planned Parenthood affiliates and 41 affiliate sites.

2005-2007 \$500,000 – Gynuity Health Projects – Packard Foundation – De-medicalization of Mifepristone Medical Abortion in the U.S.

2003-2004 \$590,000 – Watson Pharmaceuticals – The Use of Spirabrush Brush Biopsy Instrument in the Triage of Women Screened with Papsure for Cervical Dysplasia, PS-SB 175.03

2003-2004 \$18,000 – Partnership with Johns Hopkins Bloomberg School of Public Health, Pilot Study of Partner Involvement in Contraceptive Counseling at Abortion Clinics

1997-1998 Co-Investigator – Multicenter National Trial Assessing Safety and Acceptability of Cyclo-Provera in U.S. Women

1993 \$70,000 – Wyeth-Ayerst Pharmaceuticals – “The Effect of Ethinyl Estradiol vs. Ibuprofen vs. Placebo to Reduce Bleeding and Spotting in Norplant Users”

1993 \$5,000 – Chesapeake Physicians Research and Education Contraceptive and Lifestyle Follow-up of Adolescent Obstetrical Patients

1992 \$4,730 – Chesapeake Physicians Research Grant – “Survey to Explore the Interrelationships between Family Structure, Social Network, Sexual Behavior, Substance Abuse and Sexually Transmitted Diseases”

1992 \$5,000 – Johns Hopkins University, Department of Gynecology/Obstetrics Departmental Grant – “Survey to Explore the Interrelationships Between Family Structure, Social Network, Sexual Behavior, Substance Abuse and Sexually Transmitted Diseases”

MEDICAL CONTINUING EDUCATION (Only includes grants obtained directly by Vanessa Cullins or PPFA Medical Affairs. Does not include grants obtained by PPFA's Development Division)

2008-Ongoing **Minding the Contraceptive Gap**
The National Campaign to Prevent Teen and Unwanted Pregnancy - \$80,000
Watson - \$50,000

- 2007-2008 **HPV Tool Kit:**
Merck - \$250,000
Glaxo Smith Kline - \$17,000
Hologic - \$30,000
- 2007-2008 **Contraceptive Continuation:**
Wyeth - \$100,000
- 2007-2008 **Contraception – Case Based Approach**
Ortho - \$100,000
- 2006 **You Decide – Putting Contraceptive Risks into Perspective Tool Kit**
Ortho - \$261,500
- 2005 **You Decide – Putting Contraceptive Risks into Perspective – Collaboration with Association of Reproductive Health Professionals to Develop CME Content**
Ortho - \$60,483

MEDICAL CONTINUING EDUCATION (Grants obtained by PPFA's Development Division)

- 2007-2008 **Contraceptive Continuation:**
Bixby Foundation - \$200,000
- 2007-2008 **Intersections Between Environmental and Reproductive Health**
Cedar Tree Foundation - \$150,000

SERVICE DELIVERY PROGRAMS

- 1997 \$200,000 – Abell Foundation – Funding to provide an Intensive Case Management Program to Prevent Adolescent Pregnancy at Baltimore City Health Department
- 1997 \$100,000 – Strauss Foundation – Funding to Replicate the Michael Carrera Adolescent Pregnancy Prevention Program at Baltimore City Health Department
- 1994-1995 \$119,000 – Abell Foundation – Family Planning Outreach and Family Planning Clinic Services
- 1993-1994 \$195,190 – Abell Foundation – Family Planning Outreach and Family Planning Clinic Services
- The Family Planning Outreach Service Group delivered presentations to high risk populations located on the Bayview Research Campus and in the Baltimore Metropolitan Area, and provided individual, in home, family planning to high risk clients referred from Baltimore City Department of Social Services, Child Protective Services.
- 1992 \$24,475.50 – Abell Foundation – Production of a Norplant Video for adolescents and other high-risk populations

1992 \$100,000 – Abell Foundation – Contraceptive Outreach, Family Planning Clinic

AD HOC PEER REVIEWER

2007-2009 Continuous Identification of Research Evidence (CIRE) System: WHO Medical Eligibility reviews of newly published evidence

1998-2000 Studies in Family Planning, Women's Health in Primary Care, Bulletin of the World Health Organization

1998-2002 Review of Technical Documents developed by or in conjunction with World Health Organization, Family Health International, or UNFPA

1995 American Journal of Obstetrics and Gynecology

1995 Archives of Pediatrics and Adolescent Medicine

ROUND TABLE PANELIST OR AUTHOR OR CO-DEVELOPER OF ASSOCIATED MONOGRAPH

2012 Panelist – “Black Women's Health and the Affordable Care Act”
2012 National Association of Black Journalists (NABJ) Convention & Career Fair, New Orleans, LA

2012 Panelist – “African-American Women's Reproductive Health and the 2012 Elections” 2012 NABJ Media Institute on Health: Health Policy and Health Inequities, Washington, DC

2012 Panelist – “The Pill: Over the Counter and Under Your Control”
Civil Liberties & Public Policy Program Conference, “From Abortion Rights to Social Justice,” Hampshire College, Amherst, MA

1998-1999 Editorial Board – Dialogues in Vaginitis Newsletters (4 total) – CME Program; Sponsored by Pro-Com International and Johns Hopkins University School of Medicine, Baltimore, MD

1996 **Cullins VE.** Contraceptive Update: Norplant. Women of Color Reproductive Health Forum. Half Moon Bay Resort, Jamaica. April 4-7, 1996:5-8.

1996 **Cullins VE.** Intrauterine Devices: Women of Color Reproductive Health Forum. Half Moon Bay Resort, Jamaica. April 4-7, 1996:9-10.

1997 Vulvovaginitis – Causes and Therapies: An update of the National Institute of Child Health and Human Development. Clinical Courier Vol. 16, No. 7, July 1997. Produced and copyrighted by Gardiner-Caldwell SynerMed

1995 Vulvovaginitis – Associate Monograph – Vulvovaginitis: A Practice Protocol for the Managed Care Clinician. National Association of Managed Care Physicians Roundtable Highlights Vol. 1, No. 7. January, 1996. Produced and copyrighted by Gardiner-Caldwell SynerMed

FDA WRITTEN COMMENTS AND PRESENTATIONS TO ADVISORY COMMITTEES

- 2011 Oral testimony to FDA regarding VTE risk in drospirenone containing products
- 2011 Written testimony to FDA regarding VTE risk in drospirenone containing products
- 2011 Oral testimony to FDA regarding VTE risk in Ortho Evra
- 2011 Written testimony to FDA regarding VTE risk in Ortho Evra
- 2011 Oral testimony during hearing regarding ella[®], ulipristal acetate (UPA), as a medication that can be used for safe and effective emergency contraception up to 120 hours (five days) after unprotected intercourse,
- 2005 Remarks on CDER's current risk communication strategies for human drugs
- 2003 Remarks regarding docket number 01P-0075-"Switch Status of Emergency Contraceptive from Rx to OTC"

COMMENTS TO GOVERNMENTAL AGENCIES ABOUT PUBLIC HEALTH AND CLINICAL HEALTH AND HEALTHCARE

- 2010 Comments on Mapping Meaningful Use Objectives to Medical Specialties and Small Practices
- 2009 Comments for the Healthy People 2020 Objectives

PRESENTATIONS ABOUT THE AFFORDABLE CARE ACT

- 2011 What's At Stake? How Far is Florida Behind in Implementing the Affordable Care Act? Florida Community College, Jacksonville, FL, November 10, 2011
- 2011 Obstacles to Women's Health and What CLUW Members Can Do - Coalition of Labor Union Women (CLUW) 16th Biennial Convention, Orlando, FL, September 7, 2011

SELECT MEDIA INTERVIEWS & BLOGS

National Public Radio (NPR)

- 2011 *Tell Me More* Interview: Growing Controversy Surrounds 'Telemed' Abortions, January 24, 2011
- 2009 *Morning Edition* Interview: Why Accidents (The Pregnant Kind) Happen, April 20, 2009
- 2006 *Weekend Edition Saturday* Interview: FDA Investigating Two Deaths from Abortion Pill, March 18, 2006
- 2003 *The Tavis Smiley Show* Interview: Roe v. Wade, January 22, 2003

Huffington Post Blog

- 2012 Early Cancer Detection Saves Lives, August 4, 2012
- 2012 Birth Control Is a Critical Health Need, June 28, 2012

- 2012 Time to Make Our Health a Priority, May 14, 2012
- 2012 HIV-Positive Women Need Better Birth Control Options, February 29, 2012
- 2011 Why Parents Need to Talk to Their Kids about Sex, October 5, 2011
- 2011 Time to Start Talking, September 15, 2011
- 2011 Why Birth Control with No Co-Pay Will Help African-American Women, August 4, 2011
- 2010 It's Too Big? It Won't Fit? Not Everybody is Magnum, August 26, 2012
- 2010 The Pill Turns 50, June 7, 2010
- 2010 Get Yourself Tested for STDs! April 6, 2010
- 2010 Abortion, Unintended Pregnancy, and the African American Community, March 30, 2010
- 2010 HPV Vaccine for Men and Boys, Too, February 5, 2010
- 2010 Can I Get Chlamydia from a Toilet Seat? January 10, 2010
- 2009 Precious' Gabourney Sidibe Talks Sexual Health, November 11, 2009
- 2009 Dr. Vanessa Cullins: My Partner Has Herpes. Cheater? November 9, 2009
- 2009 Dr. Vanessa Cullins: Let's Talk About Sex, November 3, 2009

Adhoc Media interviews about Reproductive & Sexual Health issues including health care access, health disparities, and the affordable care act

2005-2012 Featured in Momsrising.org Radio Show, Blisstree.com, Ebody.com, The Washington Post, Essence.com, Cosmopolitan Magazine, Associate Press, Politico.com, RH Reality Check, MS Magazine, USA Today, Chicago Tribune, BET.com, and The Post-Standard (Syracuse, NY)

SELECT EDITORIALS/COMMENTARIES

1. **Cullins VE.** Journal of Women's Health. Commentary. June 1996;5(3):247-249.
2. **Cullins V, Wimberly Y.** Birth Control is a Critical Health Need [op-ed]. Huffington Post Website. June 28, 2012. Available at: http://www.huffingtonpost.com/vanessa-cullins/birth-control-is-a-critical-health-need_b_1608968.html. Accessed on August 20, 2012.
3. **Cullins V.** Make Birth Control Affordable [op-ed]. The New York Times. July 19, 2011:A23.

PUBLICATIONS

1. **Cullins VE, Anasti J, Huggins GR.** Vaginal evisceration with pneumoperitoneum. A case report. *J Reprod Med.* June 1989;34(6):426-8.
2. **Cullins VE, Huggins GR.** Non-Malignant Vulvovaginal Disorders. In: Barker LR, Burton JR, Zieve P, eds. Principles of Ambulatory Medicine. 3rd ed. Philadelphia: Williams & Wilkins; 1990.
3. **Cullins VE, Huggins GR.** Adolescence: Disorders leading to amenorrhea. *Contemp Ob Gyn.* 1990;35(9):67.
4. **Huggins GR, Cullins VE.** Fertility after contraception or abortion. *Fertil Steril.* 1990;54(4):559-73.

5. **Cullins VE**. Adolescent Pregnancy: Challenge to the Primary Care Physician. *The Female Patient*. 1991;16:27.
6. Bellantoni MF, Harman SM, **Cullins VE**, Englehardt SM, Blackman MR. Transdermal estradiol with oral progestin: biological and clinical effects in younger and older postmenopausal women. *J Gerontol*. 1991;46(6):M216-22.
7. **Cullins VE**, Johnson TRB, Repke JT. Shoulder Dystocia: An Organized Approach. *The Female Patient*. April 1991;16.
8. **Cullins VE**. The Adolescent's First Gynecologic Examination. *Med Aspects of Human Sexuality*. November 1991:56-59.
9. Huggins GR, **Cullins VE**. Adolescent Contraception. Carpenter SE, Rodk JA, eds. *Pediatric and Adolescent Gynecology*. New York, NY: Raven Press Ltd; 1992:341-352.
10. **Cullins VE**, Remsburg RE, Blumenthal PD, Huggins GR. Norplant – Welcome new contraceptive option. *Contemp Ob Gyn*. July 1992;37(7):46-60.
11. **Cullins VE**. Injectable and implantable contraceptives. *Curr Opin Obstet Gynecol*. 1992;4(4):536-43.
12. **Cullins VE**, Blumenthal PD, Remsburg RE, Huggins GR. Preliminary experience with Norplant in an inner city population. *Contraception*. 1993;47(2):193-203.
13. Emerling JM, Paluzzi P, Leiva J, **Cullins VE**. Subdermal contraceptive implants in nurse-midwifery practice. *J Nurse Midwifery*. 1993;38(2 suppl):80S-87S.
14. **Cullins VE**, Remsburg RE, Blumenthal PD, Huggins GR. Comparison of adolescent and adult experiences with Norplant, levonorgestrel contraceptive implants. *Obstet Gynecol*. 1994;83(6):1026-32.
15. Blumenthal PD, Wilson LE, Remsburg RE, **Cullins VE**, Huggins GR. Contraceptive outcomes among post-partum and post-abortual adolescents. *Contraception* 1994;50(5)451-60.
16. **Cullins VE**, Huggins GR. Non-Malignant Vulvovaginal and Cervical Disorders. In: Barker LR, Burton JR, Zieve PD, eds. *Principles of Ambulatory Medicine*. 4th ed. Philadelphia: Williams & Wilkins; 1995.
17. **Cullins VE**. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. *J Reprod Med*. 1996;41(5 suppl):428-33.
18. **Cullins VE**. The Norplant Systems (levonorgestrel implants). A fifth-year report on the US experience. Special Issue. *Contemp Ob Gyn*. November 1996:2-16.
19. **Cullins VE**, Garcia FAR. Implantable hormonal and emergency contraception. *Curr Opin Obstet Gynecol*. 1997;9(3):169-74.

20. **Cullins VE**, Huggins GR. Non-Malignant Vulvovaginal and Cervical Disorders. In: Barker LR, Burton JR, Zieve PD, eds. *Principles of Ambulatory Medicine*. 5th ed. Philadelphia: Williams & Wilkins; 1999.
21. **Cullins VE**, Dominguez L, Guberski T, Secor RM, Wysocki SJ. Treating Vaginitis. *Nurse Pract*. 1999;24(10):46,49-50,53-8,64-5(quiz).
22. **Cullins VE**, Wright TC Jr, Beattie KJ, Pollack AE. Cervical Cancer Prevention Using Visual Screening Methods. *Reproductive Health Matters*. November 1999;7(14):134-43.
23. Zabin LS, Huggins GR, Emerson MR, **Cullins VE**. Partner Effects on a Woman's Intention to Conceive: 'Not with This Partner'. *Fam Plann Perspect*. 2000;32(1):39-45.
24. **Cullins VE**, Huggins GR: Adolescent Contraception. In: Carpenter SEK, Rock JA, eds. *Pediatric and Adolescent Gynecology*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:364-92.
25. Pati S, **Cullins VE**. Female Sterilization: What's the Evidence? *Obstetrics & Gynecology Clinics of North America*. 2000;27(4):859-99.
26. **Cullins VE**, Pati S. Contraceptive Update and Thoughts About How Socio-Cultural and Economic Evolution Will Affect Contraception for India in the New Millennium. In: Pandey LK, Pandey S, eds. *Frontiers in Human Reproduction*; 2001.
27. **Cullins VE**. Sterilization. Long-Term Issues. In: Sciarra J, Blumenthal PD, eds. *Practical Gynecology: A guide for the Primary Care Physician*. Philadelphia: American College of Physicians; 2000.
28. **Cullins VE**. Garcia, FAR. Contraception. In: Ryden J, Blumenthal PD, eds. *Practical Gynecology: A Guide for the Primary Care Physician*. Philadelphia: American College of Physicians; 2002:102-56.
29. Stone MH, Westley E, **Cullins VE**. Emergency contraception: America's best kept secret. *Contemp Ob Gyn*. 2002;47(3):106-117.
30. Baill IC, **Cullins VE**, Pari S. Counseling issues in tubal sterilization. *Am Fam Physician*. 2003;67(6):1287-94.
31. Archer DF, **Cullins VE**, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) contraceptive efficacy. *Contraception*. 2004;69(3):189-95.
32. Patel A, Talmont E, Morfesis J, Pelta M, Gatter M, Momtaz MR, Piotrowski H, **Cullins V**. Planned Parenthood Federation of America Buccal Misoprostol Waiver Group: Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. *Contraception*. April 2006;73(4):420-30.
33. Shulman LP, Bateman LH, Creinin MD, **Cullins V**, Doyle LL, Godfrey E, Murphy P, Rodriguez P, Spear SJ, Stewart FH, Thomas MA, Westhoff CL, Worthington S. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation:

evidence-based clinical science should guide FDA decision making. *Contraception*. 2006;73(5):440-2.

34. **Cullins VE**. The state of contraception care in the United States today: perspectives from the Planned Parenthood Federation of America. *Manag Care Interface*. 2006;19(suppl A):5-10,20.
35. Fine P, Ball C, Pelta M, McIntyre C, Momtaz M, Morfesis J, **Cullins V**, Rash RM. Treatment of external genital warts at Planned Parenthood Federation of America centers. *J Reprod Med*. 2007;52(12):1090-6.
36. Archer DF, Philput CB, Levine AS, **Cullins VE**, Stovall TG, Bacon J, Weber ME: Effects of ethiny estradiol and ibuprofen compared to placebo on endometrial bleeding, cervic postcoital test in levonorgestrel subcutaneous implant users. *Contraception*. 2008;78(2):106-12.
37. Sivin I, Trussell J, Lichtenberg ES, Fjerstad M, Cleland K, **Cullins V**. Unexpected Heaping in Reported Gestational Age for Women Undergoing Medical Abortion. *Contraception*. September 2009;80(3):287-91.
38. Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, **Cullins V**. Rates of serious infection after changes in regimens for medical abortion. *N Engl J Med*. July 9, 2009;361(2):145-51.
39. Fjerstad M. Sivin I, Lichtenberg ES, Trussell J, Cleland K, **Cullins VE**. Effectiveness of Medical Abortion with Mifepristone and Buccal Misoprostol 59 Gestational Days. *Contraception*. September 2009;80(3)282-6.
40. Fine P, Mathé H, Ginde S, **Cullins V**, Morfesis J, Gainer E. Ulipristal acetate taken 49-120 hours after intercourse for emergency contraception. *Obstet Gynecol*. February 2010;115(2 Pt 1):257-63.
41. Fjerstad M, Trussell J, Lichtenberg ES, Sivin I, **Cullins V**. Severity of infection following the introduction of new infection control measures for medical abortion. *Contraception*. April 2011;84(4):330-335.
42. **Cullins V**. Counseling women considering combined hormonal contraception. In: Barss VA, ed. Watham, MA: *UpToDate*; 2009-2012.